Opaleye Management Inc. Aveo Pharmaceuticals, Inc. Transaction History

Opaleye Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.51 - $6.67 $842,400 - $1.6 Million	-240,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $73,710 - $140,634	-23,400 Reduced 8.88%	240,000 $1.34 Million
Q4 2021 Feb 14, 2022	SELL	$4.69 - $7.4 $901,418 - $1.42 Million	-192,200 Reduced 42.19%	263,400 $1.24 Million
Q3 2021 Nov 16, 2021	SELL	$5.12 - $6.89 $979,968 - $1.32 Million	-191,400 Reduced 29.58%	455,600 $2.82 Million
Q2 2021 Aug 16, 2021	SELL	$6.21 - $7.45 $1.17 Million - $1.4 Million	-188,000 Reduced 22.51%	647,000 $4.26 Million

Q1 2021 May 18, 2021	BUY	$5.97 - $15.28 $4.63 Million - $11.9 Million	776,200 Added 1320.07%	835,000 $6.11 Million
Q4 2020 Feb 12, 2021	BUY	$5.08 - $6.68 $298,704 - $392,784	58,800 New	58,800 $339,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.